Skip to main content Accessibility help
×
Home
  • Print publication year: 2012
  • Online publication date: August 2012

7 - Evidence-based pharmacotherapy of generalized anxiety disorder

References

Allgulander C (2009). Generalized anxiety disorder (GAD): from now to DSM-V. Psychiatric Clinics of North America 32, 611–628.
Allgulander C (2010). Novel approaches to treatment of generalised anxiety disorder. Current Opinion in Psychiatry 23, 37–42.
Allgulander C, Dahl AA, Austin C et al. (2004). Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. American Journal of Psychiatry 161, 1642–1649.
Allgulander C, Florea I, Huusom AK (2006). Prevention of relapse in generalized anxiety disorder by escitalopram treatment. International Journal of Neuropsychopharmacology 9, 495–505.
Allgulander C, Hackett D, Salinas E (2001). Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. British Journal of Psychiatry 179, 15–22.
Angst J, Gamma A, Baldwin DS et al. (2009). The generalized anxiety spectrum: prevalence, onset, course and outcome. European Archives of Pyschiatry and Clinical Neuroscience 259, 37–45.
Baldwin DS (2004). Sexual dysfunction associated with antidepressant drugs. Expert Opinion on Drug Safety 3, 457–470.
Baldwin DS, Ajel K (2007). The role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment 3, 185–191.
Baldwin DS, Anderson IM, Nutt DJ et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 19, 567–596.
Baldwin DS, Bridgman K, Buis C (2006 b). Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. Journal of Psychopharmacology 20, 91–96.
Baldwin DS, Huusom AKT, Maehlum E (2006 a). Escitalopram and paroxetine in the treatment of generalised anxiety disorder. Randomised, double-blind, placebo-controlled study. British Journal of Psychiatry 189, 264–272.
Baldwin DS, Lawson R, Wood R, Taylor D (2011 a). Systematic review and meta-analysis of the efficacy of drug therapies for generalised anxiety disorder. British Medical Journal 342, d1199 (pico version 342; 637).
Baldwin DS, Montgomery SA, Nil R, Lader M (2007 b). Discontinuation symptoms in depression and anxiety disorders. International Journal of Neuropsychopharmacology 10, 73–84.
Baldwin DS, Moreno R, Briley M (2008). Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Human Psychopharmacology 23, 527–532.
Baldwin DS, Polkinghorn C (2005). Evidence-based pharmacotherapy of generalized anxiety disorder. International Journal of Neuropsychopharmacology 8, 293–302.
Baldwin DS, Reines EH, Guiton C, Weiller E (2007 a). Escitalopram therapy for major depression and anxiety disorders. Annals of Pharmacotherapy 41, 1583–1592.
Baldwin DS, Schweizer E, Xu Y, Lyndon G (2011 b). Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR? European Neuropsychopharmacology. E-pub ahead of print.
Baldwin DS, Stein DJ, Dolberg OT, Bandelow B (2009). How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Human Psychopharmacology 24, 269–275.
Baldwin DS, Waldman S (2009). Antipsychotic drugs in the treatment of generalized anxiety disorder. International Journal of Psychiatry in Clinical Practice 13 (Suppl. 1), Sll.
Ballenger JC (1999). Clinical guidelines for establishing remission in patients with depression and anxiety. Journal of Clinical Psychiatry 60 (Suppl. 22), 29–34.
Bandelow B, Baldwin DS, Dolberg OT et al. (2006). What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? Journal of Clinical Psychiatry 67, 1428–1434.
Bandelow B, Chouinard G, Bobes J et al. (2010). Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. International Journal of Neuropsychopharmacology 13, 305–320.
Bandelow B, Seidler-Brandler U, Becker A et al. (2007). Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World Journal of Biological Psychiatry 8, 175–187.
Bandelow B, Zohar J, Hollander E et al. (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World Journal of Biological Psychiatry 9, 248–312.
Bech P (2007). Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 40, 163–168.
Beekman AT, Bremmer MA, Deeg DJ et al. (1998). Anxiety disorders in later life: a report from the longitudinal Aging Study Amsterdam. International Journal of Geriatric Psychiatry 13, 717–726.
Beesdo K, Knappe S, Pine DS (2009). Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatric Clinics of North America 32, 483–524.
Bodkin JA, Allgulander C, Llorca PM et al. (2009). Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder. ACNP 4th Annual Meeting Final Programme, 6–10 December 2009, Hollywood, Florida (www.acnp.org/ asset.axd?id = a55d7404–334e-43df-a40c-9cda68719743).
Brawman-Mintzer O, Knapp RG, Nietert PJ (2005). Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. Journal of Clinical Psychiatry 66, 1321–1325.
Brawman-Mintzer O, Knapp RG, Rynn M et al. (2006). Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 67, 874–881.
Bruce SE, Yonkers KA, Otto MW et al. (2005). Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. American Journal of Psychiatry 162, 1179–1187.
Canadian Psychiatric Association (2006). Clinical practice guidelines. Management of anxiety disorders. Canadian Journal of Psychiatry 51, 9S–91S.
Carney CE, Segal ZV, Edinger JD, Krystal AD (2007). A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. Journal of Clinical Psychiatry 68, 254–260.
Cervena K, Matousek M, Prasko J et al. (2005). Sleep disturbances in patients treated for panic disorder. Sleep Medicine 6, 149–153.
Chessick CA, Allen MH, Thase M et al. (2006). Azapirones for generalized anxiety disorder. Cochrane Database of Systematic Reviews 3, CD006115.
Davidson JR, Bose A, Korotzer A, Zheng H (2004). Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depression and Anxiety 19, 234–240.
Davidson JR, DuPont RL, Hedges D, Haskins JT (1999). Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry 60, 528–535.
Davidson JRT, Wittchen H-U, Llorca P-M et al. (2008). Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. European Neuropsychopharmacology 18, 673–681.
Downing RW, Rickels K (1985). Early treatment response in anxious outpatients treated with diazepam. Acta Psychiatrica Scandinavica 72, 522–528.
El-Khayat R, Baldwin DS (1998). Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder. Journal of Psychopharmacology 12, 323–329.
Eriksson H, Mezhebovsky I, Magi K et al. (2008). Double-blind, randomised study of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with generalized anxiety disorder. International Journal of Psychiatry in Clinical Practice 12, 322–333.
European Medicines Agency (2005). Committee for Medicinal products for Human Use (CHMP). Guideline on the clinical investigation of medicinal products indicated for generalised anxiety disorder. CPMP/EWP/4284/02, London, January 2005.
Fava M (2000). Weight gain and antidepressants. Journal of Clinical Psychiatry 61 (Suppl. 11), 37–41.
Feltner D, Wittchen HU, Kavoussi R et al. (2008). Long-term efficacy of pregabalin in generalized anxiety disorder. International Clinical Psychopharmacology 23, 18–28.
Feltner DE, Crockatt JG, Dobovsky SJ et al. (2003). A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 23, 240–249.
Food and Drug Administration (FDA) (2006). New controversial clinical trial design gives better long-term data. FDA Week, 10 May 2006.
Gao K, Sheehan DV, Calabrese JR (2009). Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Reviews in Neurotherapeutics 9, 1147–1158.
Garner M, Möhler H, Stein DJ, Mueggler T, Baldwin DS. (2009). Research in anxiety disorders: from the bench to the bedside. European Neuropsychopharmacology 19, 381–390.
Geddes JR, Carney SM, Davies C et al. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361, 653–661.
Gelenberg AJ, Lydiard B, Rudolph RL et al. (2000). Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder. Journal of the American Medical Association 283, 3082–3088.
Goodman WK, Bose A, Wang Q (2005). Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. Journal of Affective Disorders 87, 161–167.
Gould RA, Otto MW, Pollack MH, Yap L (1997). Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: a preliminary meta-analysis. Behaviour Therapy 28, 285–305.
Guy W (1976). The clinical global impression severity and impression scales. In ECDEU Assessment Manual for Psychopathology (pp. 218–222). Rockville, MD: US Department of Health, Education and Welfare.
Hackett D, White C, Salinas E (2000). Relapse prevention in patients with generalised anxiety disorder (GAD) by treatment with venlafaxine ER. Poster presented at 1st International Forum on Mood and Anxiety Disorders, Monte Carlo, November 2000 (www.aimgroup.it/2000/ifmad/POSTER20. htm). Accessed 6 July 2010.
Hallberg P, Sjoblom V (2005). The use of selective serotonin inhibitors during pregnancy and breast-feeding: a review and clinical aspects. Journal of Clinical Psychopharmacology 25, 59–73.
Hamilton M (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology 32, 50–55.
Hartford J, Kornstein S, Liebowitz M et al. (2007). Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. International Clinical Psychopharmacology 22,167–174.
Hewett K, Adams A, Bryson H et al. (2001). Generalized anxiety disorder: efficacy of paroxetine. Paper presented at the 7th World Congress of Biological Psychiatry, Berlin, Germany.
Hidalgo RB, Tupler LA, Davidson JRT (2007). An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. Journal of Psychopharmacology 21, 864–872.
Hoyer J, Gloster AT (2009). Psychotherapy for generalized anxiety disorder: don't worry, it works! Psychiatric Clinics of North America 32, 629–640.
Hunot V, Churchill R, Silva de Lima M et al. (2007). Psychological therapies for generalized anxiety disorder [Review]. Cochrane Database of Systematic Reviews 24, CD001848.
Judd LL, Kessler RC, Paulus MP et al. (1998). Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Survey (NCS). Acta Psychiatrica Scandinavica 98 (Suppl. 393), 6–11.
Kasper S, Herman B, Nivoli G et al. (2009). Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. International Clinical Psychopharmacology. Published online: January 2009. doi:10.1097/YIC.0b013e 32831d7980.
Katzman M, Brawman-Mintzer O, Reyes E et al. (2008 a). Extended release quetiapine fumarate (quetiapine XR) monotherapy in long-term treatment of generalized anxiety disorder (GAD): efficacy and tolerability results from a randomized, placebo-controlled trial. Biological Psychiatry 63 (Suppl.), 141S.
Katzman MA, Vermani M, Jacobs L et al. (2008 b). Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. Journal of Anxiety Disorders 22, 1480–1486.
Kessler RC, DuPont RL, Berglund P (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. American Journal of Psychiatry 156, 1915–1923.
Khan A, Joyce M, Atkinson S et al. (2011). A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 31, 418–428.
Kinrys G, Vasconcelos e Sa D, Nery F (2007). Adjunctive zonisamide for treatment refractory anxiety. International Journal of Clinical Practice 61, 1050–1053.
Koponen H, Allgulander C, Erickson J et al. (2007). Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Primary Care Companion Journal of Clinical Psychiatry 9, 100–107.
Laakmann G, Schtile C, Lorkowski G et al. (1998). Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology 136, 357–366.
Lenox-Smith AJ, Reynolds A (2003). A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. British Journal of General Practice 53, 772–777.
Lenze EJ, Rollman BL, Shear MK et al. (2009). Escitalopram for older adults with generalised anxiety disorder: a randomized controlled trial. Journal of the American Medical Association 301, 295–303.
Leonardo ED, Hen R (2008). Anxiety as a developmental disorder. Neuropsychopharmacology 33, 134–140.
Levinson-Castiel R, Merlob P, Linder N et al. (2006). Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Archives of Paediatric and Adolescent Medicine 160, 173–176.
Maina G, Albert U, Salvi V, Bogetto F (2004). Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. Journal of Clinical Psychiatry, 63, 391–395.
Martens EJ, de Jonge P, Na B et al. (2010). Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease. Archives of General Psychiatry 67, 750–758.
Martin JLR, Sainz-Pardo M, Furukawa TA et al. (2007). Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. Journal of Psychopharmacology 21, 774–782.
Mathew SJ, Price RB, Mao X et al. (2008). Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biological Psychiatry 63, 891–898.
Meredith C, Cutler AJ, She F, Eriksson H (2011). Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. International Clinical Psychopharmacology 27(1), 40–54.
Michelson D, Amsterdam JD, Quitkin FM et al. (1999). Changes in weight during a 1-year trial of fluoxetine. American Journal of Psychiatry 156, 1170–1176.
Misri S, Reebye P, Kendrick K et al. (2006). Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. American Journal of Psychiatry 163, 1026–1032.
Mitte K, Noack P, Steil R, Hautzinger M (2005). A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. Journal of Clinical Psychopharmacology 25, 141–150.
Montgomery S, Chatamra K, Pauer L et al. (2008). Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. British Journal of Psychiatry 193, 389–394.
Montgomery SA, Mclntyre RS, Szamosi J et al. (2009). Extended release quetiapine fumarate monotherapy in patients with MDD: a pooled analysis of sustained response data from studies D1448C00001 and D1448C00002. International Journal of Psychiatry in Clinical Practice 13 (Suppl. 1), S39.
Montgomery SA, Sheehan DV, Meoni P et al. (2002). Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. Journal of Psychiatric Research 36, 209–217.
Montgomery SA, Tobias K, Zornberg GL et al. (2006). Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Journal of Clinical Psychiatry 67, 771–782.
Morris PLP, Dahl AA, Kutcher S et al. (2003). Efficacy of sertraline for the acute treatment of generalized anxiety disorder. European Neuropsychopharmacology 13, S375.
Munk-Jorgensen P, Allgulander C, Dahl AA et al. (2006). Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatric Services 57, 1738–1744.
Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ (1986). Review of the side-effect profile of buspirone. American Journal of Medicine 31, 17–21.
Nitschke JB, Sarinopoulos I, Oathes DJ et al. (2009). Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. American Journal of Psychiatry 166, 302–310.
Olatunji BO, Feldman G, Smits JAJ et al. (2008). Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. Depression and Anxiety 25, 167–171.
Pande AC, Crockatt JG, Feltner DE et al. (2003). Pregabalin in generalized anxiety disorder: a placebo-controlled trial. American Journal of Psychiatry 160, 533–540.
Pande AC, Crockatt MA, Janne C, Feltner DE (2000). Pregabalin treatment of GAD. Presented at the 153rd Annual Meeting of the American Psychiatric Association, Chicago, IL, 13–18 May (Abstract NR244) (http://www. psych.org/edu/other_res/ lib_archives/archives/meetings/2000nra).
Perugi G, Frare F, Toni C et al. (2002). Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid depression or dysthymia: effectiveness, tolerability and predictors of response. Neuropsychobiology 46, 145–149.
Pinheiro SN, Laprega MR, Furtado EF (2005). Psychiatric morbidity and alcohol use by pregnant women in a public obstetric service. Revista Saude Publica 39, 593–598.
Pohl RB, Feltner DE, Fieve RR, Pande AC (2005). Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. Journal of Clinical Psychopharmacology 25, 151–158.
Pollack MH, Kornstein SG, Spann ME et al. (2008). Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. Journal of Psychiatric Research 42, 1176–1184.
Pollack MH, Meoni P, Otto MW et al. (2003). Predictors of outcome following venlafaxine extended-release treatment of DSM–IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. Journal of Clinical Psychopharmacology 23, 250–259.
Pollack MH, Simon NM, Zalta AK et al. (2006). Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biological Psychiatry 59, 211–215.
Pollack MH, Zaninelli R, Goddard A et al. (2001). Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 62, 350–357.
Rickels K, Downing R, Schweizer E, Hassman H (1993). Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry 50, 884–895.
Rickels K, Etemad B, Khalid-Khan S et al. (2010). Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Archives of General Psychiatry 67, 1274–1281.
Rickels K, Pollack MH, Feltner DE et al. (2005). Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Archives of General Psychiatry 62, 1022–1030.
Rickels K, Pollack MH, Sheehan DV, Haskins JT (2000). Efficacy of extended-release venlafaxine in non-depressed outpatients with generalized anxiety disorder. American Journal of Psychiatry 157, 968–974.
Rickels K, Rynn M, Iyengar M, Duff D (2006). Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. Journal of Clinical Psychiatry 67, 41–47.
Rickels K, Schweizer E, Csanalosi I et al. (1988). Long-term treatment of anxiety and risk of withdrawal: prospective study of clorazepate and buspirone. Archives of General Psychiatry 45, 444–450.
Rickels K, Zaninelli R, McCafferty J et al. (2003). Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry 160, 749–756.
Rodriguez BF, Weisberg RB, Pagano ME et al. (2006). Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. Journal of’Nervous and Mental Disease 194, 91–97.
Rondo PHC, Ferreira RF, Nogueira F et al. (2003). Maternal psychological stress and distress as predictors of low birth weight, prematurity and intrauterine growth retardation. European Journal of Clinical Nutrition 57, 266–272.
Royal College of Psychiatrists (1997). Benzodiazepines: Risks, Benefits or Dependence. A Re-evaluation. Council Report CR59. London: Royal College of Psychiatrists.
Rynn M, Khalid-Khan S, Garcia-Espana F (2006). Early response and 8-week treatment outcome in GAD. Depression and Anxiety 23, 461–465.
Rynn MA, Riddle MA, Yeung PP, Kunz NR. (2007). Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. http://www.ncbi.nlm.nih.gov/pubmed/17267793
Rynn MA, Russell J, Erickson J et al. (2008). Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive titration, placebo-controlled trial. Depression and Anxiety 25, 182–189.
Rynn MA, Siqueland L, Rickels K (2001). Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. American Journal of Psychiatry 158, 2008–2014.
Simon NM, Connor KM, LeBeau RT et al. (2008). Quetiapine augmentation of paroxetine CR for the treatment of generalized anxiety disorder: preliminary findings. Psychopharmacology (Berlin) 197, 675–681.
Simon NM, Zalta AK, Worthington III JJ et al. (2006). Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depression and Anxiety 23, 373–376.
Smoller JW, Block SR, Young MM (2009). Genetics of anxiety disorders: the complex road from DSM to DNA. Depression and Anxiety 26, 965–975.
Stein DJ, Ahokas AA, de Bodinat C (2008 b). Agomelatine in generalized anxiety disorder: a randomized, placebo-controlled study. Journal of Clinical Psychopharmacology 28, 561–566.
Stein DJ, Andersen HF, Goodman WK (2005). Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Annals of Clinical Psychiatry 17, 71–75.
Stein DJ, Baldwin DS, Baldinetti F, Mandel F (2008 a). Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. European Neuropsychopharmacology 18, 422–430.
Stein DJ, Baldwin DS, Dolberg OT et al. (2006). Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. Journal of Clinical Psychiatry 67, 1741–1746.
Stocchi F, Nordera G, Jokinen RH et al. (2003). Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. Journal of Clinical Psychiatry 64, 250–258.
Tyrer P, Baldwin DS (2006). Generalised anxiety disorder. Lancet 368, 2156–2166.
Tyrer P, Owen R, Dawling S (1983). Gradual withdrawal of diazepam after long-term therapy. Lancet 321, 1402–1406.
Tyrer P, Seivewright H, Johnson T (2004). The Nottingham Study of Neurotic Disorder: predictors of 12 year outcome of dysthymic, panic and generalised anxiety disorder. Psychological Medicine 34, 385–394.
Weaver J, Miceli J, Shiovitz T et al. (2009). Adjunctive pregabalin after partial response to SSRI or SNRI in GAD: results of a double-blind, placebo-controlled trial. European Neuropsychopharmacology 19 (Suppl. 3), S593–S594.
Weiller E, Bisserbe JC, Maier W, Lecrubier Y (1998). Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO Study on Psychological Problems in General Health Care. British Journal of Psychiatry 173 (Suppl. 34), 18–23.
Weissman MM, Pilowsky DJ, Wickramaratne PJ et al. (2006). Remissions in maternal depression and child psychopathology. A STAR*D-Child report. Journal of the American Medical Association 295, 1389–1398.
Whalen PJ, Johnstone T, Somerville LH et al. (2008). A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Biological Psychiatry 63, 858–863.
Wittchen H-U, Carter RM, Pfisster H et al. (2000). Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. International Clinical Psychopharmacology 15, 319–328.
Wittchen H-U, Jacobi F (2005). Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies. European Neuropsychopharmacology 15, 357–376.
Wittchen H-U, Kessler RC, Beesdo K et al. (2002). Generalized anxiety disorder and depression in primary care: prevalence, recognition, and management. Journal of Clinical Psychiatry 63 (Suppl. 8), 24–34.